Fortress Biotech, Inc. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how Fortress Biotech performed this year. Think of this as a friend-to-friend breakdown rather than a dense financial document.

1. What does this company do?

Fortress Biotech operates like a venture capital firm for medicine. They identify promising drug candidates, form separate "subsidiary" companies to develop them, and guide those teams through clinical trials. Their portfolio includes Mustang Bio (cell therapy), Avenue Therapeutics (neurology), Checkpoint Therapeutics (oncology), and Journey Medical Corporation (dermatology).

2. Financial Performance

Fortress is currently in a "heavy lifting" phase. For 2023, the company reported $81.3 million in revenue, compared to $86.5 million in 2022. Much of this income is driven by Journey Medical Corporation, specifically through sales of Qbrexza (for sweating) and the launch of Emrosi (for rosacea). Because the company relies heavily on these specific products, their overall financial health is tied closely to the market performance of this small group of drugs.

3. Major Wins and Challenges

• The Strategy: Their model spreads risk across many projects. If one drug fails, the entire company doesn't necessarily collapse.
• The Hurdle: The company requires consistent cash flow to fund operations. They reported a loss of $88.5 million for 2023. To cover these costs, they frequently issue new shares or take on debt. This results in "dilution," where the issuance of new shares reduces the percentage of the company owned by existing shareholders.

4. Financial Health

At the end of 2023, the company held $68.7 million in cash against a significant debt load. Their history of losses and negative cash flow means they must continue to raise capital to maintain operations.

• Dividend Alert: The board has paused dividend payments on preferred stock to preserve cash, and there is no guarantee these payments will resume.
• Revenue Risks: Several of Journey’s products face potential competition from generic alternatives, which could impact the revenue stream the company relies on for survival.

5. Key Risks

• Dilution: Frequent share issuance to raise cash has increased the total number of shares outstanding, which can lower the value of individual holdings.
• Clinical Success: The business model is inherently speculative. If their subsidiaries fail to secure FDA approval for their drug candidates, the value of those investments could drop significantly.
• Patent Cliffs: The lack of long-term patent protection for certain dermatology products creates a risk that generic competitors could enter the market and reduce sales.

6. Future Outlook

Fortress is focused on moving its current pipeline toward completion while managing its debt. Their success over the next two years depends on their ability to raise additional capital or achieve commercial success with their current drug portfolio, such as Checkpoint’s Cosibelimab.

Investor Takeaway: Fortress Biotech is a high-risk, high-reward play. It is best suited for those who understand that the company’s survival is tied to the success of specific clinical trials and their ability to navigate a challenging cash-flow environment. If you are considering an investment, look closely at their upcoming clinical trial results and their ability to fund operations without further diluting your stake.